The growth of immunotherapies has shifted the standard of care for treating many solid tumors. As new indications are approved, there is a growing need for clinician education in this space. To that end, the Society for Immunotherapy of Cancer (SITC) and PlatformQ Health partnered to develop a two-part educational series focused on:
- Managing patients on immunotherapy
- Barriers to clinical trials
- Biomarker testing
Led by faculty from Stanford Cancer Institute, Memorial Sloan Kettering Cancer Center, Yale Comprehensive Cancer Center, and MD Anderson Cancer Center, the sessions focused on emerging approaches in treating small cell lung cancer and non-small cell lung cancer, gastroesophageal junction cancer, and colorectal cancer.
The program outcomes were shared at the 2022 SITC Annual Meeting.
1,173 learners participated in the program, with 83 percent of learners reporting that the activity positively impacted their clinical practice while 95 percent of learners reported that the activity positively impacted patient experiences or outcomes. Through competence assessment questions, the PlatformQ Health Outcomes team demonstrated that learners achieved a significant improvement in knowledge across all key areas.